SPRB Stock Overview
A biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Spruce Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.43 |
| 52 Week High | US$5.95 |
| 52 Week Low | US$0.36 |
| Beta | 2.34 |
| 1 Month Change | -22.14% |
| 3 Month Change | -8.18% |
| 1 Year Change | -85.47% |
| 3 Year Change | -90.73% |
| 5 Year Change | n/a |
| Change since IPO | -97.50% |
Recent News & Updates
Shareholder Returns
| SPRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.7% | -1.7% | -1.1% |
| 1Y | -85.5% | -5.0% | 22.4% |
Return vs Industry: SPRB underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: SPRB underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| SPRB volatility | |
|---|---|
| SPRB Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPRB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SPRB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 22 | Javier Szwarcberg | www.sprucebiosciences.com |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
Spruce Biosciences, Inc. Fundamentals Summary
| SPRB fundamental statistics | |
|---|---|
| Market cap | US$18.07m |
| Earnings (TTM) | -US$39.43m |
| Revenue (TTM) | US$7.10m |
2.5x
P/S Ratio-0.4x
P/E RatioIs SPRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRB income statement (TTM) | |
|---|---|
| Revenue | US$7.10m |
| Cost of Revenue | US$36.06m |
| Gross Profit | -US$28.96m |
| Other Expenses | US$10.47m |
| Earnings | -US$39.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -407.83% |
| Net Profit Margin | -555.23% |
| Debt/Equity Ratio | 4.2% |
How did SPRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 07:28 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spruce Biosciences, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Martin Auster | Credit Suisse |
| Raghuram Selvaraju | H.C. Wainwright & Co. |